Board & ownership
- Board
- 7 members
- Auditor
- BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
- Lawrence BlattDirector
- Lawrence M BLATTDirector
- Maha KatabiDirector
- Max KlementDirector
- Pierre Raboisson BVDirector
and 2 other directors
Summary
The computed 12-month bankruptcy probability of COULTREON BIOPHARMA is 3.0% (moderate). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals. No annual accounts have been filed with the National Bank.
Overview
Activity
Manufacture of basic pharmaceutical products and pharmaceutical preparations
NACE 21201Other research and development on natural sciences NACE 72109
1 site
Size
No accounts filed yet
Financial health
- Bankruptcy probabilitywithin 12 months
- 3.0%
No score: no figures
Structure
- Board
- 7 members
Auditor: BDO BEDRIJFSREVISOREN-BDO REVISEURS D'ENTREPRISES
Signalsraises riskFounded in 20251 change of registered office in 24 monthslowers riskSector: Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)No annual accounts with figuresShow the evidence
Bankruptcy probability
Bankruptcy probability, 12 months
3.0%
Moderate
0%0.5%1.5%4%10%≥ 25%
About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
02-2026: 2.4%lowest value
03-2026: 2.4%● unchanged vs 02-2026lowest value
04-2026: 2.4%● unchanged vs 03-2026
05-2026: 2.5%▲ +0.1 percentage points vs 04-2026
06-2026: 2.6%▲ +0.1 percentage points vs 05-2026
07-2026: 2.9%▲ +0.3 percentage points vs 06-2026
08-2026: 2.9%● unchanged vs 07-2026
09-2026: 3.0%▲ +0.1 percentage points vs 08-2026highest value
10-2026: 3.0%● unchanged vs 09-2026
Credit check for your own amount and term
Show the recommended maximum and see how the verdict changes with amount, term and advance.
Signals
Four signals.
lowers riskraises risk
Searched, nothing found (1)
- Appointment: BDO BEDRIJFSREVISOREN BV (statutory auditor)Permanent representative: Ellen LOMBAERTS
- Capital & shares · Amendment of…Correction · Capital
- Resignations: PIERRE RABOISSON BV, Lawrence M…Appointments: PIERRE RABOISSON BV, Lawrence…
Key points
By topic
Network & group
- Connected companies
- 2
Timeline
- Events
- 8
- Since
- 2025
- 20-04-2026Name
- 02-03-2026Resignation: Vuldex Consulting BV (director)
- 01-12-2025Appointments: Pierre Raboisson BV (managing director and…
Company details
- Sites
- 1
- Legal form
- Private limited company
- Activity
- Manufacture of basic pharmaceutical products and pharmaceutical preparationsNACE 21201
- Founded
- 30-01-2025
- Peppol
- Reachable for e-invoices
Articles of association
- Provisions read
- 64
- Who signs
- Two directors jointly
- Financial year
- From 1 January to 31 December
- Annual meeting
- Second Wednesday of June at 17:00
- Purpose
- “Het ontplooien van diverse activiteiten die rechtstreeks of onrechtstreeks betrekking…” (deed in Dutch)
Go further with this company
How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check What support did similar companies receive that this one did not?Subsidies Who is behind this young company, and which other companies do they have?Network investigator
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.